Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.402 EUR | +1.52% | -8.32% | -12.61% |
Mar. 25 | GenSight: share price falls, limited financial visibility | CF |
Mar. 22 | GenSight Biologics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2023 | 3M 3.24M | Sales 2024 * | 4.4M 4.74M | Capitalization | 31.4M 33.86M |
---|---|---|---|---|---|
Net income 2023 | -26M -28.04M | Net income 2024 * | -26M -28.04M | EV / Sales 2023 | 8.55 x |
Net Debt 2023 * | 29.4M 31.7M | Net Debt 2024 * | 57.8M 62.33M | EV / Sales 2024 * | 20.3 x |
P/E ratio 2023 |
-0.85
x | P/E ratio 2024 * |
-0.71
x | Employees | 23 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 90.77% |
Latest transcript on GenSight Biologics S.A.
1 day | +1.52% | ||
1 week | -8.32% | ||
Current month | +1.52% | ||
1 month | +2.81% | ||
3 months | -13.46% | ||
6 months | -38.53% | ||
Current year | -12.61% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 21-05-18 | |
Thomas Gidoin
DFI | Director of Finance/CFO | 41 | 15-05-31 |
Scott Jeffers
CTO | Chief Tech/Sci/R&D Officer | - | 22-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Wyzga
CHM | Chairman | 69 | 13-09-30 |
Peter Goodfellow
BRD | Director/Board Member | 72 | 14-05-31 |
José-Alain Sahel
FOU | Founder | 68 | 11-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.402 | +1.52% | 55,204 |
24-03-27 | 0.396 | -1.00% | 78,279 |
24-03-26 | 0.4 | -0.25% | 57,643 |
24-03-25 | 0.401 | -10.29% | 301,125 |
24-03-22 | 0.447 | +1.94% | 36,323 |
Real-time Euronext Paris, March 28, 2024 at 12:35 pm EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.61% | 33.92M | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |